approval
saveVRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approval
community read0 votes
Sponsor: ABBVIE. Form: CAPSULE. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalVRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approvalDec 18, 2025 · 287d ago
- approvalVRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approvalDec 18, 2025 · 287d ago
- approvalVRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approvalDec 18, 2025 · 287d ago
- approvalVRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approvalDec 18, 2025 · 287d ago
- approvalCARIPRAZINE HYDROCHLORIDE — FDA approvalDec 16, 2025 · 289d ago
- approvalVRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approvalNov 22, 2024 · 678d ago
- approvalVRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approvalDec 16, 2022 · 1385d ago
- approvalVRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approvalMay 24, 2019 · 2687d ago
same company · ±60 days · 6
- approvaldivalproex sodium DR: DEPAKOTE (DIVALPROEX SODIUM) — FDA approvalMar 6, 2017
- approvaldivalproex sodium DR: DEPAKOTE (DIVALPROEX SODIUM) — FDA approvalMar 6, 2017
- approvaldivalproex sodium DR: DEPAKOTE ER (DIVALPROEX SODIUM) — FDA approvalMar 6, 2017
- approvallinaclotide: LINZESS (LINACLOTIDE) — FDA approvalMar 8, 2017
- approvallinaclotide: LINZESS (LINACLOTIDE) — FDA approvalJan 25, 2017
- approvaladalimumab: HUMIRA (ADALIMUMAB) — FDA approvalMar 27, 2017
comments(0)
5-min edit window · permanent after that